The CAIRIBU U24 Interactions Core curates and maintains a collection of funding opportunities for CAIRIBU-affiliated investigators. This includes grants from the National Institutes of Health, institution-specific funding aimed at enhancing stakeholder engagement in research, and various funding sources that support non-malignant urologic research.
NIDDK Funding Annoucements
Time-Sensitive Evaluation of Policies Affecting Health Behaviors and Chronic Disease Risk (R01-Clinical Trial Not Allowed)
Time-Sensitive Evaluation of Policies Affecting Health Behaviors and Chronic Disease Risk (R01-Clinical Trial Not Allowed) This Notice of Funding Opportunity (NOFO) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence diet, physical activity, sleep, and/or weight and thus has the potential to lower rates of chronic diseases, particularly in populations at risk for health disparities. [Posted 1/10/2025. Expires 1/12/2028]
Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) The National Institutes of Health (NIH) hereby notify Program Directors/Principal Investigators (PD(s)/PI(s)) holding specific types of NIH research grants listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. [Posted 10/9/2020. Expires 9/30/2025]
Notice of Special Interest (NOSI): Administrative Supplement for Continuity of Biomedical and Behavioral Research Among First-Time Recipients of NIH Research Project Grant Awards
Notice of Special Interest (NOSI): Administrative Supplement for Continuity of Biomedical and Behavioral Research Among First-Time Recipients of NIH Research Project Grant Awards This is the reissuance of Notice of Special Interest (NOSI): Administrative Supplement for Continuity of Biomedical and Behavioral Research Among First-Time Recipients of NIH Research Project Grant Awards (NOT-OD-20-055). The overarching goal of this program is to enhance the retention of investigators facing critical life events who are transitioning to the first renewal of their first independent research project grant award or to a second new NIH research project grant award. [Posted 12/1/2022. Expires 10/1/2025]
Notice of Special Interest: Administrative Supplements to Promote Research Continuity and Retention of NIH Mentored Career Development (K) Award Recipients and Scholars
Notice of Special Interest: Administrative Supplements to Promote Research Continuity and Retention of NIH Mentored Career Development (K) Award Recipients and Scholars This is the reissuance of Notice of Special Interest (NOSI): Administrative Supplements to Promote Research Continuity and Retention of NIH Mentored Career Development (K) Award Recipients and Scholars (NOT-OD-20-054). The overarching goal of this program is to enhance the retention of investigators facing critical life events who are transitioning from mentored career development awards to research independence and to minimize departures from biomedical research workforce. [Posted 12/1/2022. Expires 10/1/2025]
HEAL Initiative: Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices (RM1 Clinical Trial Optional)
HEAL Initiative: Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices (RM1 Clinical Trial Optional) This notice of funding opportunity (NOFO) is designed to support interdisciplinary research teams of multiple PDs/PIs to investigate the mechanism of action of pain relief by medical devices with the overall goal of optimizing therapeutic outcomes for FDA-approved or -cleared technologies. [Posted 4/27/2023. Expires 6/10/2025]
- More NIDDK Funding posts
Other NIH Funding Annoucements
Supporting Talented Early Career Researchers in Genomics (R01 Clinical Trial Optional)
Supporting Talented Early Career Researchers in Genomics (R01 Clinical Trial Optional) This Notice of Funding Opportunity is intended to identify and support research projects by exceptionally promising Early Stage Investigators with a long-term career interest in pursuing innovative research in genomics. This opportunity is open to research in all areas relevant to the mission of NHGRI, including genomic sciences, genomic medicine, genomic data science, and ethical, legal, and social implications (ELSI) of genomics. [Posted 12/16/2024. Expires 2/27/2027]
Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)
Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional) The Joint NINDS/NIMH Exploratory Neuroscience Research Grant program supports exploratory and innovative research projects, which fall within the missions of the NINDS and NIMH. Awards will provide support for the early and conceptual stages of projects. [Posted 1/8/2025. Expires 1/8/2028]
Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Not Allowed)
Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Not Allowed) The Joint NINDS/NIMH Exploratory Neuroscience Research Grant program supports exploratory and innovative research projects, which fall within the missions of the NINDS and NIMH. [Posted 1/8/2025. Expires 1/8/2025]
Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)
Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed) The purpose of this Notice of Funding Opportunity (NOFO) is to encourage grant applications for investigator-initiated prospective observational comparative effectiveness research (CER) to the National Institute of Neurological Disorders and Stroke (NINDS) (note: only prospective observational studies will be considered). [Posted 1/8/2025. Expires 9/8/2025]
Interventions on Health and Healthcare Disparities on Non-Communicable and Chronic Diseases in Latin America: Improving Health Outcomes Across the Hemisphere (R01 – Clinical Trial Required)
Interventions on Health and Healthcare Disparities on Non-Communicable and Chronic Diseases in Latin America: Improving Health Outcomes Across the Hemisphere (R01 - Clinical Trial Required) The purpose of this Notice of Funding Opportunity (NOFO) is to support innovative and interdisciplinary team research focused on clinical, health services, and/or community-based interventions that address health and healthcare disparities related to non-communicable and chronic diseases (NCDs) with the highest disease burden and mortality in Latin America and among U.S. Hispanics/Latinos. [Posted 1/13/2025. Expires 5/8/2027]
- More Other NIH Funding posts
Other Funding Announcements
Innovative Science Accelerator Program (ISAC)
The ISAC Award provides seed funding for exceptionally innovative, disruptive (high-risk/high-reward) research relevant to Kidney-Urologic-Hematologic communities that has the potential to lead to groundbreaking or paradigm-shifting results that will change the field. [Next deadline 9/17/2025]
- More Other Funding posts
Aging-Related Funding Announcements
Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required)
Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required). This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated clinical trials requiring an extended project period of 6 or 7 years. The trials can be any phase, must be hypothesis-driven, and related to the research mission of the participating IC. Consultation with IC staff is strongly encouraged prior to the submission of the clinical trial implementation application. This FOA is not intended for support of clinical trials that do not require an extended project period of 6 or 7 years. [Posted on 1/15/2023. Expires on 1/14/2026]
NIA Career Transition Award (K22 Independent Clinical Trial Not Allowed)
NIA Career Transition Award (K22 Independent Clinical Trial Not Allowed). The purpose of the NIA K22 Career Transition Award is to facilitate the transition of mentored, postdoctoral researchers to tenure-track or equivalent faculty positions conducting research that advances the mission of NIA. This award does not provide postdoctoral phase funding; therefore, candidates should be prepared to transition to tenure-track or equivalent faculty positions within 12 months after confirmation of a positive funding decision. After transition to an approved faculty position at an extramural institution/organization, the award will provide three years of protected research time through salary and research support. [Posted on 2/13/2024. Expires on 11/13/2025]
NIA Academic Leadership Career Award (K07 Independent Clinical Trial Not Allowed)
NIA Academic Leadership Career Award (K07 Independent Clinical Trial Not Allowed). The purpose of this notice of funding opportunity (NOFO) is to provide support for established investigators who have the expertise and leadership skills to enhance aging and/or Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) research capacity within their academic institution. [Posted on 11/6/2024. Expires on 11/13/2027]
NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required)
NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required). This Notice of Funding Opportunity (NOFO) invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). The trials should be hypothesis-driven, milestone-defined, and related to NIA's research mission. Information about NIA's mission can be found on the NIA website. [Posted on 11/6/2024. Expires on 1/8/2026]
Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed). This Notice of Funding Opportunity (NOFO) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states. [Posted on 11/6/2024. Expires on 1/8/2026]
- More Aging-Related Funding Posts
Institution-Specific CTSA Stakeholder Engagement Funding Announcements
University of Wisconsin-Madison – Institute for Clinical & Translational Research (ICTR) Funding
See all funding opportunities from University of Wisconsin-Madison.
University of Alabama at Birmingham – Center for Clinical & Translational Science (CCTS) Funding
See all funding opportunities from University of Alabama at Birmingham.
University of California San Francisco – Clinical & Translational Science Institute (CTSI) Funding
See all funding opportunities from University of California San Francisco.
University of Michigan – Michigan Institute for Clinical and Health Research (MICHR) Funding
See all funding opportunities from University of Michigan.
University of Pennsylvania – Institute for Translational Medicine and Therapeutics (ITMAT) Funding
See all funding opportunities from University of Pennsylvania.
University of Pittsburgh – Clinical and Translational Science Institute (CTSI) Funding
See all funding opportunities from University of Pittsburgh.
- More Institution-Specific CTSA Stakeholder Engagement Funding posts
NIH Data Book – The NIH Data Book (NDB) provides basic summary statistics on extramural grants and contract awards, grant applications, the organizations that NIH supports, the trainees and fellows supported through NIH programs, and the national biomedical workforce.